Matches in SemOpenAlex for { <https://semopenalex.org/work/W3029143432> ?p ?o ?g. }
Showing items 1 to 36 of
36
with 100 items per page.
- W3029143432 endingPage "1393" @default.
- W3029143432 startingPage "1391" @default.
- W3029143432 abstract "糖尿病视网膜病变(diabetic retinopathy,DR)是糖尿病的严重并发症之一,是各国主要致盲性眼病.玻璃体腔注射血管内皮生长因子(VEGF)单克隆抗体bevacizumab(商品名Avastin)是治疗DR的一种安全、有效、经济方法,但有关其长期疗效及重复注射的安全性尚存在争议。" @default.
- W3029143432 created "2020-06-05" @default.
- W3029143432 creator A5028831140 @default.
- W3029143432 creator A5039920775 @default.
- W3029143432 creator A5064510573 @default.
- W3029143432 creator A5088982440 @default.
- W3029143432 date "2013-11-10" @default.
- W3029143432 modified "2023-09-25" @default.
- W3029143432 title "玻璃体腔内注射Avastin治疗糖尿病视网膜病变研究进展" @default.
- W3029143432 doi "https://doi.org/10.3760/cma.j.issn.1006-4443.2013.11.005" @default.
- W3029143432 hasPublicationYear "2013" @default.
- W3029143432 type Work @default.
- W3029143432 sameAs 3029143432 @default.
- W3029143432 citedByCount "0" @default.
- W3029143432 crossrefType "journal-article" @default.
- W3029143432 hasAuthorship W3029143432A5028831140 @default.
- W3029143432 hasAuthorship W3029143432A5039920775 @default.
- W3029143432 hasAuthorship W3029143432A5064510573 @default.
- W3029143432 hasAuthorship W3029143432A5088982440 @default.
- W3029143432 hasConcept C118487528 @default.
- W3029143432 hasConcept C556039675 @default.
- W3029143432 hasConcept C71924100 @default.
- W3029143432 hasConceptScore W3029143432C118487528 @default.
- W3029143432 hasConceptScore W3029143432C556039675 @default.
- W3029143432 hasConceptScore W3029143432C71924100 @default.
- W3029143432 hasIssue "11" @default.
- W3029143432 hasLocation W30291434321 @default.
- W3029143432 hasOpenAccess W3029143432 @default.
- W3029143432 hasPrimaryLocation W30291434321 @default.
- W3029143432 hasVolume "31" @default.
- W3029143432 isParatext "false" @default.
- W3029143432 isRetracted "false" @default.
- W3029143432 magId "3029143432" @default.
- W3029143432 workType "article" @default.